PMID- 17891134
OWN - NLM
STAT- MEDLINE
DCOM- 20080108
LR  - 20220330
IS  - 1087-0156 (Print)
IS  - 1546-1696 (Electronic)
IS  - 1087-0156 (Linking)
VI  - 25
IP  - 10
DP  - 2007 Oct
TI  - Renal clearance of quantum dots.
PG  - 1165-70
AB  - The field of nanotechnology holds great promise for the diagnosis and treatment 
      of human disease. However, the size and charge of most nanoparticles preclude 
      their efficient clearance from the body as intact nanoparticles. Without such 
      clearance or their biodegradation into biologically benign components, toxicity 
      is potentially amplified and radiological imaging is hindered. Using 
      intravenously administered quantum dots in rodents as a model system, we have 
      precisely defined the requirements for renal filtration and urinary excretion of 
      inorganic, metal-containing nanoparticles. Zwitterionic or neutral organic 
      coatings prevented adsorption of serum proteins, which otherwise increased 
      hydrodynamic diameter by >15 nm and prevented renal excretion. A final 
      hydrodynamic diameter <5.5 nm resulted in rapid and efficient urinary excretion 
      and elimination of quantum dots from the body. This study provides a foundation 
      for the design and development of biologically targeted nanoparticles for 
      biomedical applications.
FAU - Choi, Hak Soo
AU  - Choi HS
AD  - Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess 
      Medical Center, 330 Brookline Avenue, Room SL-B05, Boston, Massachusetts 02215, 
      USA.
FAU - Liu, Wenhao
AU  - Liu W
FAU - Misra, Preeti
AU  - Misra P
FAU - Tanaka, Eiichi
AU  - Tanaka E
FAU - Zimmer, John P
AU  - Zimmer JP
FAU - Itty Ipe, Binil
AU  - Itty Ipe B
FAU - Bawendi, Moungi G
AU  - Bawendi MG
FAU - Frangioni, John V
AU  - Frangioni JV
LA  - eng
GR  - R21 EB000673-01/EB/NIBIB NIH HHS/United States
GR  - 1U54-CA119349/CA/NCI NIH HHS/United States
GR  - R33 EB000673/EB/NIBIB NIH HHS/United States
GR  - GM68762/GM/NIGMS NIH HHS/United States
GR  - R33 EB000673-04/EB/NIBIB NIH HHS/United States
GR  - R21 EB000673/EB/NIBIB NIH HHS/United States
GR  - U54 CA119349/CA/NCI NIH HHS/United States
GR  - P50 GM068762/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20070923
PL  - United States
TA  - Nat Biotechnol
JT  - Nature biotechnology
JID - 9604648
RN  - 0 (Contrast Media)
SB  - IM
MH  - Animals
MH  - Contrast Media
MH  - Diagnostic Imaging
MH  - Drug Stability
MH  - Kidney/*metabolism
MH  - Male
MH  - Nanotechnology
MH  - Particle Size
MH  - *Quantum Dots
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC2702539
MID - NIHMS56431
EDAT- 2007/09/25 09:00
MHDA- 2008/01/09 09:00
PMCR- 2009/06/28
CRDT- 2007/09/25 09:00
PHST- 2007/04/13 00:00 [received]
PHST- 2007/08/16 00:00 [accepted]
PHST- 2007/09/25 09:00 [pubmed]
PHST- 2008/01/09 09:00 [medline]
PHST- 2007/09/25 09:00 [entrez]
PHST- 2009/06/28 00:00 [pmc-release]
AID - nbt1340 [pii]
AID - 10.1038/nbt1340 [doi]
PST - ppublish
SO  - Nat Biotechnol. 2007 Oct;25(10):1165-70. doi: 10.1038/nbt1340. Epub 2007 Sep 23.